Usrc Kent Llc is a medicare approved dialysis facility center in Kent, Ohio and it has 13 dialysis stations. It is located in Portage county at 1720 East Main Street, Kent, OH, 44240. You can reach out to the office of Usrc Kent Llc at (330) 346-0467. This dialysis clinic is managed and/or owned by Us Renal Care, Inc.. Usrc Kent Llc has the following ownership type - Profit. It was first certified by medicare in February, 2017. The medicare id for this facility is 362853 and it accepts patients under medicare ESRD program.
| Name | Usrc Kent Llc |
|---|---|
| Location | 1720 East Main Street, Kent, Ohio |
| No. of Dialysis Stations | 13 |
| Medicare ID | 362853 |
| Managed By | Us Renal Care, Inc. |
| Ownership Type | Profit |
| Late Shifts | No |
| 1720 East Main Street, Kent, Ohio, 44240 | |
| (330) 346-0467 | |
| Not Available |
News Archive
An appeals court has upheld a 30-year prison term for a Medicare fraudster in Florida. Dr. Ana Alvarez-Jacinto, a Miami endocrinologist, was convicted of health care fraud and sentenced to 30 years behind bars.
A new study from the Johns Hopkins Bloomberg School of Public Health and the Chronic Kidney Disease Prognosis Consortium (CKD-PC) found that in general chronic kidney disease is similarly associated with a higher risk of death and end stage renal disease for both women and men. The findings were released online in advance of publication in BMJ.
Sheffield Teaching Hospitals NHS Foundation Trust has seen one of the biggest rises in the number of research studies it is offering to its patients, according to a national league table of NHS research activity published by the National Institute for Health Research Clinical Research Network today (Tuesday 26 October).
Chembio Diagnostics, Inc., which develops, manufactures, markets and licenses point-of-care diagnostic tests, has been notified that Bio-Manguinhos, a division of the Oswaldo Cruz Foundation of Brazil ("FIOCRUZ"), has received regulatory approval from Brazil's National Health Surveillance Agency (Anvisa) to market Chembio's Dual Path Platform (DPP®) HIV 1/2 rapid test for use with oral fluid, blood, serum or plasma samples. The approval triggers $400,000 in license revenues payable to Chembio within 120 days of the date of approval.
› Verified 3 days ago
| NPI Number | 1639522949 |
| Organization Name | U.s. Renal Care Kent Dialysis |
| Doing Business As | Usrc Kent, Llc |
| Address | 1720 E Main St Kent, Ohio, 44240 |
| Phone Number | (330) 346-0467 |
News Archive
An appeals court has upheld a 30-year prison term for a Medicare fraudster in Florida. Dr. Ana Alvarez-Jacinto, a Miami endocrinologist, was convicted of health care fraud and sentenced to 30 years behind bars.
A new study from the Johns Hopkins Bloomberg School of Public Health and the Chronic Kidney Disease Prognosis Consortium (CKD-PC) found that in general chronic kidney disease is similarly associated with a higher risk of death and end stage renal disease for both women and men. The findings were released online in advance of publication in BMJ.
Sheffield Teaching Hospitals NHS Foundation Trust has seen one of the biggest rises in the number of research studies it is offering to its patients, according to a national league table of NHS research activity published by the National Institute for Health Research Clinical Research Network today (Tuesday 26 October).
Chembio Diagnostics, Inc., which develops, manufactures, markets and licenses point-of-care diagnostic tests, has been notified that Bio-Manguinhos, a division of the Oswaldo Cruz Foundation of Brazil ("FIOCRUZ"), has received regulatory approval from Brazil's National Health Surveillance Agency (Anvisa) to market Chembio's Dual Path Platform (DPP®) HIV 1/2 rapid test for use with oral fluid, blood, serum or plasma samples. The approval triggers $400,000 in license revenues payable to Chembio within 120 days of the date of approval.
› Verified 3 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 8 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 26 |
| Percentage of adult patients getting regular hemodialysis at the center | |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
An appeals court has upheld a 30-year prison term for a Medicare fraudster in Florida. Dr. Ana Alvarez-Jacinto, a Miami endocrinologist, was convicted of health care fraud and sentenced to 30 years behind bars.
A new study from the Johns Hopkins Bloomberg School of Public Health and the Chronic Kidney Disease Prognosis Consortium (CKD-PC) found that in general chronic kidney disease is similarly associated with a higher risk of death and end stage renal disease for both women and men. The findings were released online in advance of publication in BMJ.
Sheffield Teaching Hospitals NHS Foundation Trust has seen one of the biggest rises in the number of research studies it is offering to its patients, according to a national league table of NHS research activity published by the National Institute for Health Research Clinical Research Network today (Tuesday 26 October).
Chembio Diagnostics, Inc., which develops, manufactures, markets and licenses point-of-care diagnostic tests, has been notified that Bio-Manguinhos, a division of the Oswaldo Cruz Foundation of Brazil ("FIOCRUZ"), has received regulatory approval from Brazil's National Health Surveillance Agency (Anvisa) to market Chembio's Dual Path Platform (DPP®) HIV 1/2 rapid test for use with oral fluid, blood, serum or plasma samples. The approval triggers $400,000 in license revenues payable to Chembio within 120 days of the date of approval.
› Verified 3 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Usrc Kent Llc with elevated calcium levels.
| Patients with hypercalcemia | 8 |
| Hypercalcemia patient months | 26 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | |
| Patients with Serumphosphor | 9 |
| Patients with Serumphosphor less than 3.5 mg/dL | |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | |
| Patients with Serumphosphor greater than 7 mg/dL |
News Archive
An appeals court has upheld a 30-year prison term for a Medicare fraudster in Florida. Dr. Ana Alvarez-Jacinto, a Miami endocrinologist, was convicted of health care fraud and sentenced to 30 years behind bars.
A new study from the Johns Hopkins Bloomberg School of Public Health and the Chronic Kidney Disease Prognosis Consortium (CKD-PC) found that in general chronic kidney disease is similarly associated with a higher risk of death and end stage renal disease for both women and men. The findings were released online in advance of publication in BMJ.
Sheffield Teaching Hospitals NHS Foundation Trust has seen one of the biggest rises in the number of research studies it is offering to its patients, according to a national league table of NHS research activity published by the National Institute for Health Research Clinical Research Network today (Tuesday 26 October).
Chembio Diagnostics, Inc., which develops, manufactures, markets and licenses point-of-care diagnostic tests, has been notified that Bio-Manguinhos, a division of the Oswaldo Cruz Foundation of Brazil ("FIOCRUZ"), has received regulatory approval from Brazil's National Health Surveillance Agency (Anvisa) to market Chembio's Dual Path Platform (DPP®) HIV 1/2 rapid test for use with oral fluid, blood, serum or plasma samples. The approval triggers $400,000 in license revenues payable to Chembio within 120 days of the date of approval.
› Verified 3 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 1 |
| Patient months included in arterial venous fistula and catheter summaries | 5 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer |
News Archive
An appeals court has upheld a 30-year prison term for a Medicare fraudster in Florida. Dr. Ana Alvarez-Jacinto, a Miami endocrinologist, was convicted of health care fraud and sentenced to 30 years behind bars.
A new study from the Johns Hopkins Bloomberg School of Public Health and the Chronic Kidney Disease Prognosis Consortium (CKD-PC) found that in general chronic kidney disease is similarly associated with a higher risk of death and end stage renal disease for both women and men. The findings were released online in advance of publication in BMJ.
Sheffield Teaching Hospitals NHS Foundation Trust has seen one of the biggest rises in the number of research studies it is offering to its patients, according to a national league table of NHS research activity published by the National Institute for Health Research Clinical Research Network today (Tuesday 26 October).
Chembio Diagnostics, Inc., which develops, manufactures, markets and licenses point-of-care diagnostic tests, has been notified that Bio-Manguinhos, a division of the Oswaldo Cruz Foundation of Brazil ("FIOCRUZ"), has received regulatory approval from Brazil's National Health Surveillance Agency (Anvisa) to market Chembio's Dual Path Platform (DPP®) HIV 1/2 rapid test for use with oral fluid, blood, serum or plasma samples. The approval triggers $400,000 in license revenues payable to Chembio within 120 days of the date of approval.
› Verified 3 days ago